A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib

Published:2020-06 Issue: Volume:156 Page:104686
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Chong Qing-Yun,Kok Ze-Hui,Bui Ngoc-Linh-Chi,Xiang Xiaoqiang,Wong Andrea Li-Ann,Yong Wei-Peng,Sethi Gautam,Lobie Peter E.,Wang Lingzhi,Goh Boon-Cher

Funder

National Research Foundation of Singapore

National Medical Research Council of Singapore

Publisher

Elsevier BV

Subject

Pharmacology

Reference113 articles.

1. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

2. Cyclin-dependent kinases;Malumbres;Genome Biol.,2014

3. Cell cycle proteins as promising targets in cancer therapy;Otto;Nat. Rev. Cancer,2017

4. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat. Rev. Drug Discov.,2015

5. CDK inhibitors: positive and negative regulators of G1-phase progression;Sherr;Genes Dev.,1999

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-09-13

2. CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer;Advanced Science;2024-08-13

3. Differential Expression and Prognostic Significance of CDK1 and CDK6 in Breast Cancer: A Multi-Omics Approach;2024-08-11

4. Rupatadine inhibits colorectal cancer cell proliferation through the PIP5K1A/Akt/CDK2 pathway;Biomedicine & Pharmacotherapy;2024-07

5. Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials;The Breast;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3